U.S. markets closed
  • S&P Futures

    3,847.50
    +8.50 (+0.22%)
     
  • Dow Futures

    31,580.00
    +115.00 (+0.37%)
     
  • Nasdaq Futures

    12,641.50
    -22.25 (-0.18%)
     
  • Russell 2000 Futures

    2,204.90
    +15.20 (+0.69%)
     
  • Crude Oil

    67.48
    +1.39 (+2.10%)
     
  • Gold

    1,706.30
    +7.80 (+0.46%)
     
  • Silver

    25.69
    +0.40 (+1.59%)
     
  • EUR/USD

    1.1930
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3851
    +0.0023 (+0.17%)
     
  • USD/JPY

    108.4000
    +0.0180 (+0.02%)
     
  • BTC-USD

    51,501.52
    +2,315.89 (+4.71%)
     
  • CMC Crypto 200

    1,038.88
    +95.70 (+10.15%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    29,083.14
    +218.82 (+0.76%)
     

Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Liquidia Technologies, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present at the 2020 Jefferies Virtual London Healthcare Conference at 7:55 PM GMT (2:55 PM ET) on Thursday, November 19, 2020.

A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com